AzTrials
AzTrials

Vulvar CarcinomaPhase 2NCT07672782

Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva

A Phase 2 study testing Tisotumab Vedotin in people with Vulvar Carcinoma and Recurrent or Metastatic Vulvar Cancer, run by GOG Foundation at 1 site in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This is an open-label, single arm, phase 2 study designed to evaluate the efficacy of tisotumab vedotin in participants with recurrent or metastatic squamous cell carcinoma of the vulva by estimating the objective response rate. Patients will receive tisotumab vedotin every 3 weeks (21 days plus or minus 3 days). Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
Tisotumab Vedotin
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
28 participants
Where
1 siteUnited States
Study dates
Nov 2026to Dec 2029
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥18 years, or considered an adult by local regulations, at time of consent.
  • Must sign an informed consent form (ICF) indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study prior to any other study-related assessments or procedures.
  • Has recurrent or metastatic vulva cancer with squamous cell histology, and:
  • Has not received more than 2 prior systemic therapy regimens for recurrent and/or metastatic vulva cancer. Chemotherapy administered in the adjuvant or neoadjuvant setting, or in combination with radiation therapy, should not be counted as separate systemic therapy regimen.
  • Is not a candidate for curative therapy, including but not limited to radiotherapy or exenterative surgery.
  • Measurable disease according to RECIST v1.1 as assessed by the investigator, defined as:
Show all 29Show fewer
  • A minimum of one non-nodal lesion ≥10 mm in the longest diameter from a nonirradiated area. If target lesion(s) are located within previously irradiated area only, the participant can be enrolled only if there has been demonstrated progression in the "in field" lesion and upon approval of the sponsor's medical monitor.
  • OR
  • Lymph node lesion ≥15 mm in the shortest diameter from a non-irradiated area.
  • Must demonstrate acceptable screening laboratory values:
  • Calculated eGFR (MDRD formula): ≥50 mL/min/1.73m^2
  • Alanine aminotransferase (ALT): ≤3× upper limit of normal (ULN) (if liver tumor/metastases are present, then ≤5×ULN is allowed)
  • Aspartate aminotransferase (AST): ≤3×ULN (if liver tumor/metastases are present, then ≤5×ULN is allowed)
  • Bilirubin: ≤1.5×ULN (except in participants diagnosed with Gilbert's syndrome, direct bilirubin ≤2×ULN)
  • Hemoglobin: ≥5.6 mmol/L (9.0 g/dL)
  • Absolute Neutrophil Count (ANC): ≥1500/μL (1.5x10^9/L)
  • Platelet count: ≥100×10^9/L
  • For participants NOT on anti-coagulation therapy:
  • Activated partial thromboplastin time (aPTT): ≤1.5×ULN
  • International normalized ratio (INR): ≤1.2
  • For participants on anti-coagulation therapy:
  • aPTT: ≤1.5×ULN
  • INR: ≤2.5
  • Has ECOG performance status of 0 or 1 within 28 days prior to registration.
  • Has a negative serum pregnancy test for participants of reproductive potential. Participants that are postmenopausal, permanently sterilized or previously subjected to bilateral oophorectomy, bilateral salpingectomy and/or hysterectomy can be considered as not having reproductive potential.
  • Participants of reproductive potential must agree to use adequate contraception during and for 6 months after the last study treatment administration. Adequate contraception is defined as highly effective methods of contraception. Two highly effective methods of contraception must be used in countries where this is required.
  • Must agree not to breastfeed or donate ova, starting at the time of informed consent and continuing through 6 months after receiving the last dose of study drug administration.
  • If required by local health authorities, has negative serology for hepatitis B surface antigen (HBsAg)/HBV DNA, or hepatitis C antibody (HCVAb) or RNA. Active hepatitis C is defined by a known positive HCVAb result and known quantitative HCV RNA results greater than the lower limits of detection of the assay.
  • Must be willing and able to adhere to the prohibitions and restrictions specified in the protocol.

Who cannot join

  • Has primary melanoma, adenocarcinoma, sarcomatoid, or other histologies not mentioned in inclusion criterion 3
  • Has clinically significant bleeding issues or risks:
  • Known past or current coagulation defects leading to an increased risk of bleeding
  • Diffuse alveolar hemorrhage from vasculitis
  • Known bleeding diathesis
  • Ongoing major bleeding (ie, participant requires a transfusion of >2 platelet concentrates within 14 days of the first dose of study treatment)
Show all 37Show fewer
  • Trauma with increased risk of life-threatening bleeding
  • History of severe head trauma or intracranial surgery within 8 weeks of study entry
  • Has cardiovascular issues or risks:
  • Clinically significant cardiac disease, including unstable angina or acute myocardial infarction, 6 months prior to screening
  • Any medical history of congestive heart failure (grade III or IV as classified by the New York Heart Association)
  • Any medical history of decreased cardiac ejection fraction of <45%
  • A marked baseline prolongation of QT/QTc interval (eg, repeated demonstration of a QTc interval >450 msec)
  • A complete left bundle branch block (defined as a QRS interval ≥120 msec in left bundle branch block form) or an incomplete left bundle branch block
  • Central nervous system (CNS): any history of intracerebral arteriovenous malformation, cerebral aneurysm, or stroke (transient ischemic attack >28 days prior to screening is allowed).
  • Ophthalmological: Active ocular surface disease or a history of cicatricial conjunctivitis or inflammatory conditions that predispose to cicatrizing conjunctivitis (eg, Wagner syndrome, atopic keratoconjunctivitis, autoimmune disease affecting the eyes), ocular Stevens-Johnson syndrome or toxic epidermal necrolysis, mucus pemphigoid, and participants with penetrating ocular transplants are ineligible. Cataracts alone is not an exclusion criterion.
  • Other cancer: known past or current malignancy other than inclusion diagnosis. Exceptions are malignancies with a negligible risk of metastasis or death (e.g., 5-year OS ≥90%) such as non-invasive basal cell carcinoma, non-invasive superficial bladder cancer, and ductal carcinoma in situ.
  • Brain metastases are allowed if the following criteria are met: definitive therapy (eg, surgery or stereotactic brain radiotherapy) has been completed >8 weeks before the first dose of study treatment; no evidence of clinical or radiologic progression of the brain metastases; participant has completed perioperative corticosteroid therapy or steroid taper. NOTE: Chronic steroid therapy is acceptable provided that the dose is stable for 28 days prior to study enrollment.
  • Surgery/procedures: major surgery within 4 weeks (28 days) or minor surgery within 7 days prior to the first study treatment administration. Participants must have recovered adequately from the toxicity or complications from the intervention prior to starting study treatment. Participants who have planned major surgery during the treatment period must be excluded from the study.
  • Peripheral neuropathy ≥grade 2.
  • Prior anti-cancer therapy:
  • Any prior treatment with MMAE-derived drugs (e.g. Brentuximab vedotin, Polatuzumab vedotin, Tisotumab vedotin, Disitamab vedotin).
  • Radiotherapy for palliative intent within 21 days prior to the first administration of study treatment. Participants must have recovered from all clinically significant radiation-related toxicities. At least 42 days must have elapsed from the last administration of chemo-radiotherapy to first study treatment.
  • Small molecules, chemotherapy, immunotherapy, or monoclonal antibodies within 28 days prior to the first administration of study treatment.
  • Currently participating in or has participated in a study of an investigational agent or device and received active treatment within 28 days prior to the first dose of study treatment.
  • Other:
  • Ongoing significant, uncontrolled medical condition.
  • Clinically significant active viral, bacterial, or fungal infection requiring IV or oral treatment with antimicrobial therapy ending <7 days prior to first study treatment administration.
  • Clinically relevant bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage.
  • Participants with clinical symptoms or signs of gastrointestinal obstruction and who require parenteral hydration or nutrition at the time of the first dose of study treatment.
  • Has known seropositivity of human immunodeficiency virus (HIV); known medical history of hepatitis B or C infection. Note: No testing for HIV, hepatitis B, or hepatitis C is required, unless mandated by local health authorities. Exceptions include latent or controlled HIV infection.
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (dose exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of tisotumab vedotin.
  • Is pregnant or intends to conceive children within 6 months of ending study treatment.
  • Is breast feeding and cannot discontinue breast feeding for the duration of the study and ≥6 months after the last study treatment administration.
  • Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments.
  • Known allergies, hypersensitivity, or intolerance to study treatment or its excipients (refer to the Investigator's Brochure for further information on tisotumab vedotin).
  • Has known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the study.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Sarin Chhab contact

215-854-0770

schhab@gog.org

Shanon Matkin contact

smatkin@gog.org

United States1 site

  • Atrium Health Levine Cancer Center

    Charlotte, North Carolina, 28204

    Yovanni Casablanca, MD

Other trials in United States

About this study

Official title: Phase II Study Tisotumab Vedotin in Metastatic or Recurrent Squamous Cell Carcinoma of the Vulva

This is an open-label, single arm, phase 2 study designed to evaluate the efficacy of tisotumab vedotin in participants with recurrent or metastatic squamous cell carcinoma of the vulva by estimating the objective response rate.

Patients will receive tisotumab vedotin every 3 weeks (21 days plus or minus 3 days). Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.

Being tested
Tisotumab Vedotin
Keywords
Metastatic, Recurrent, Squamous Cell Carcinoma, Vulva, Advanced, Vulvar Cancer
Medical subject headings
Vulvar Neoplasms, Recurrence, Neoplasm Metastasis, Carcinoma, Squamous Cell

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tisotumab VedotinDrug

    Also called Tisotumab vedotin-tftv, Tivdak

    Tisotumab vedotin is an antibody-drug conjugate (ADC) directed against tissue factor (TF) and is composed of an IgG1 human monoclonal antibody chemically conjugated via a protease cleavable valine citrulline linker to the drug MMAE.

Study groups in NCT07672782
Study groupRoleWhat they receive
Tisotumab vedotinExperimentalTisotumab vedotin 2.0 mg/kg IV (maximum of 200 mg for patients ≥100 kg) every 3 weeks (21 days)
Receives: Drug: Tisotumab Vedotin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall Response Rate

    Complete or partial objective tumor response as measured by CT scan, PET-CT or MRI and assessed by RECIST v. 1.1 criteria

    Measured: Measured from study enrollment then every 9 weeks for the first 36 weeks and then every 12 weeks thereafter through disease progression or completion of treatment assessed up to 5 years or study closure.

Secondary outcomes (3)

  1. Nature and Degree of Adverse Events (Safety and Toxicity)

    Nature and degree of adverse events as assessed using CTCAE v6 including frequencies and maximum grade by term and category

    Measured: Measured from the time of the first dose of study treatment until 30 days after the last dose of study treatment.

  2. Progression Free Survival

    Progression-Free Survival (PFS) is defined as the duration of time from study enrollment to time of progression or death, whichever occurs first. Disease progression will be measured by CT scan, PET-CT or MRI and assessed per RECIST 1.1.

    Measured: Measured from study enrollment then every 9 weeks for the first 36 weeks and then every 12 weeks thereafter until time of documented disease progression or death, whichever occurs first assessed up to 5 years or study closure.

  3. Overall Survival

    Overall survival (OS) is defined as the duration of time from the start of study treatment to time of death or the date of last contact.

    Measured: Measured from study enrollment to time of death or the date of last contact assessed up to 5 years or study closure.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jun 2026
  2. Study startNov 2026 (estimated)
  3. Primary completionMar 2029 (estimated)
  4. Study completionDec 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
28 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07672782
Sponsor's protocol ID
GOG-3150
Status last verified
Jun 2026
First submitted
8 Jun 2026
Last updated
29 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Tisotumab Vedotin in people with Vulvar Carcinoma and Recurrent or Metastatic Vulvar Cancer, run by GOG Foundation at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 29 inclusion and 37 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sarin Chhab (215-854-0770, schhab@gog.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall Response Rate (time frame: Measured from study enrollment then every 9 weeks for the first 36 weeks and then every 12 weeks thereafter through disease progression or completion of treatment assessed up to 5 years or study closure.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07672782.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in